Drug Evaluation
Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.
‘Wearing off’ monoclonal antibodies leads to patient dissatisfaction, depression in MS
WEST PALM BEACH, Fla. — The “wearing-off” effect with monoclonal antibodies prescribed for multiple sclerosis led to treatment dissatisfaction and was associated with depression, according to a poster from ACTRIMS 2024.
Oral ibrexafungerp provides favorable therapeutic response in patients with fungal disease
WASHINGTON — More than half of patients being treated with ibrexafungerp for challenging fungal diseases and limited treatment options saw complete or partial treatment response, according to data presented at IDWeek.
FDA panel unanimously supports CV event risk reduction indication for icosapent ethyl
The Endocrinologic and Metabolic Diseases Advisory Committee of the FDA voted 16-0 in favor of the safety and efficacy of icosapent ethyl, based on available data, to support its approval for an indication to reduce risk for CV events.